$HIMS

Schwab Network on $HIMS (Nov 10, 2026)

AI summary · Schwab Network

After a surprise loss, revenue and subscriber misses and below-consensus guidance, HIMS fell 13.5% to about $19, down almost 40% year to date. The speaker expects it to settle near here with $20 as major support, selling a December out-of-the-money put spread; he sees continued but slower growth, peptide benefits fading and double-digit growth possibly over, while still a solid company.

He framed it in months
“HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus”
Schwab NetworkPublished Nov 10 · 15 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

15 passages
0:004:25

Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.

So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.

I mean, that surprise loss, the guidance cut here, uh light sales, it was a lethal combination for him. Now we're down 13.5% continuing the drop off that we saw in after hours trade for him and hers.

Uh there were a lot of issues here. They missed on revenue. They missed on subscriptions. They missed on earnings with that surprise loss. They reported a loss of 14 cents a share.

Expectations were for earnings of 6 cents a share. So that started things off on a bad note.

Then we got revenue of $890.4 million. It was a gain of 49% year-over-year, but it did miss analyst expectations by about $3 million. So, not a huge miss, but still a miss.

They reported a net loss of $33 million for the quarter compared with a net income of 15.8 million a year ago. Consensus was looking for it to be positive $13.9 million. So, some pretty significant misses with those surprise losses coming up here.

Subscriber count was up 13% to about 2.79 million subscribers. Revenue per average subscriber also increased about 30% to $105. But again, Wall Street expected better here. That was a miss as well.

That 49% growth in the third quarter in terms of uh their revenue though was their second straight quarter of acceleration. Domestic revenue is up 21% from a year ago. International revenue increased 321%.

Um and for the current fourth quarter, HIMS expects revenue to be about 875 million to 895 million. They're projecting their Ibidon number of 70 to 90 million reflecting an IBAon margin of 8 to 10%.

All of those were underneath what the street was looking for. They were all misses pretty much across the board.

They also narrowed their fullear guidance as well to a range of 3.13 billion to 3.15 down from a prior range of 3.1 to 3.3. Ibida also got dropped and narrowed 257 to 277 million reflecting an Ibida margin of 8 to 9%.

So that may mark some contraction even on the full year over the quarterly numbers.

So I mean as we look at this Sam I mean these moves completely wiped out the gains that they saw last week after announcing this agreement with Eli Liy to sell its popular Zepbound and foundo on their platform. Uh just a tough setup for them.

They are investing heavily in AI and technology to try to drive the business long term, but right now seeing a swift move to the downside of more than 13 and a half percent, which puts them down almost 40% year to date.

Yeah, and as we mentioned, and you and I have been covering this stock for this year. I mean, that hot peptide summer didn't really materialize. I think a lot of the people on the street were kind of banking on that, but we'll have to see how that regulatory path goes.

But Marley, thanks for the details. It is getting punished right now.

Yeah, absolutely. And uh Sam, and this is a stock that, as you alluded to, is basically been, you know, just taken out to the woodshed, even more so today post earnings that were uh certainly on the surface not great, but not really terrible.

Revenue still growing, right? although be maybe a little bit below the analyst expectations.

So I look for the stock to just settle in around here. Certainly $20 on the chart looks like major support going back several quarters. So I'm hanging my hat there going out to December.

Selling a slightly out of money put spread. Now earlier it was about 10% out of the money. Selling the D 2017 put spread bringing in over a buck right now. So like that return on risk, have defined risk as well, and I can sell shorter term call spreads if I need to hedge it further.

So I think him certainly uh is a company that's going to continue to grow, albeit not at that rapid pace. You mentioned the peptides. We're not seeing the pickup there. And I think we'll stop seeing uh you know the huge benefits going forward on most of their products, but it'll still be a solid company.

I think the growth days uh of having uh doubledigit growth may be behind him but solid growth going forward at least for the future.

What this channel has said about $HIMS

Schwab Network has 3 calls on this stock; only the adjacent ones are shown.

TickerSays